Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

09 Jul 2021

1499.40

-0.68%

Rubicon Research acquires Cipla's Meditab Specialities Satara plant

Business Line

Acquisition of oral liquid, nasal inhalers facility may be completed in two months

Cipla Ltd. is trading at high day volume of 2.7M.

Cipla Ltd.

09 Jul 2021

1499.40

-0.68%

Street bets on Cipla's respiratory drug portfolio to drive growth

livemint

The strong growth in the domestic arena, led by focus on specialty and covid treatment drugs, has kept investor interest firm

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

08 Jul 2021

1499.40

-0.68%

Discussions still going on over indemnity to Moderna, says report

Business Standard

Earlier on June 29, Indian drug regulators granted permission to Cipla to import donated doses of Moderna from the US.

Cipla Ltd. is trading at high day volume of 2.7M.

Cipla Ltd.

30 Jun 2021

1499.40

-0.68%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of Nomination and Remuneration Committee and subject to approval of the shareholders at the ensuing Annual General Meeting, the Board of the Directors vide resolution dated 30th June 2021, has approved appointment of Mr. Ramesh Prathivadibhayankara Rajagopalan ('Mr. P. R. Ramesh') (DIN: 01915274) as an additional and an independent director of the Company for a period of 5 years with effect from 1st July, 2021 to 30th June 2026 (both days inclusive).

pdf

Cipla Ltd.

30 Jun 2021

1499.40

-0.68%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith copies of newspaper notice published in Business Standard (English) and Sakal (Marathi) on 30th June, 2021. The notice published is for those shareholders who have not claimed their dividend(s) for seven consecutive years or more and consequently whose shares are liable for transfer to the IEPF as per section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (including any amendments thereto or re-enactment thereof for the time being in force). This is for your information and records.

pdf

Cipla Ltd.

30 Jun 2021

1499.40

-0.68%

Cipla, Dr Reddy's Labs: Tech charts show up to 11% rally in pharma stocks

Business Standard

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla records fresh highs on nod for Moderna's Covid-19 vaccine

Business Line | 30 Jun 2021 2 more

Cipla Ltd.

30 Jun 2021

1499.40

-0.68%

Cipla gets DCGI nod to import Moderna vaccine; no commercial deal yet

Business Standard

1st mRNA vax part of US-India pact; no commercial deal yet

Cipla Ltd. is trading above its 200 day SMA of 1495.0

Moderna's Covid vaccine gets nod for restricted use

Business Line | 29 Jun 2021 9 more

Cipla Ltd.

29 Jun 2021

1499.40

-0.68%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that in response to media queries on vaccine import, the Company would be releasing the following statement: "Cipla Limited is supporting Moderna, Inc. with the regulatory approval and importation of vaccines to be donated to India. At this stage, there is no definitive agreement on commercial supplies.'

pdf

Cipla Ltd.

29 Jun 2021

1499.40

-0.68%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Cipla, Dr. Reddy's, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of investigational anti-viral drug Molnupiravir for COVID-19

pdf

Cipla Ltd.

26 Jun 2021, 11:00AM

1499.40

-0.68%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the schedule of Analyst / Institutional Investor Meeting with the Company

pdf

Is Cipla Ltd. worth buying?

624 Votes:

Buy 75.8%

Sell 13.94%

Hold 10.26%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf

High volume today

Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.